$-0.01
(Market cap
$84 Mln
Recently Viewed
Clear AllMarket cap
$84 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
14.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-29.7 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-4.3
Debt to Equity
--
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
52,479,257
CFO
$-25.72 Mln
EBITDA
$-6.29 Mln
Net Profit
$-80.01 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
OKYO Pharma Ltd ADR (OKYO)
| -22.7 | 1.3 | -25.9 | 6.0 | 8.0 | -- | -- |
|
BSE Sensex
| -8.7 | 2.7 | -5.2 | -2.4 | 8.6 | 9.8 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
OKYO Pharma Ltd ADR (OKYO)
| 80.0 | -34.8 | -7.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
OKYO Pharma Ltd ADR (OKYO)
|
1.6 | 84.5 | 0.0 | -6.6 | -- | -- | -- | 14.1 |
| 4.0 | 391.3 | 73.2 | -67.8 | -82.1 | -65.5 | -- | 5.2 | |
| 20.4 | 1,171.8 | 0.0 | -147.4 | -29,734.7 | -150.3 | -- | 6.8 | |
| 28.6 | 1,920.8 | 1,112.2 | 320.9 | -17.8 | 10.5 | 5 | 0.5 | |
| 13.5 | 2,407.3 | 550.0 | 458.1 | -3.3 | 45.9 | 5.3 | 1.9 | |
| 8.5 | 397.4 | 0.0 | -29.0 | -- | -20.4 | -- | 3.0 | |
| 16.9 | 1,178.0 | 403.3 | 22.8 | 3,081.6 | 9.1 | 417 | 4.3 | |
| 3.8 | 668.3 | 4.6 | -201.1 | -4,342.4 | -146.8 | -- | 5.5 | |
| 5.5 | 477.8 | 174.7 | -115.2 | 0.0 | -80.2 | -- | 3.8 | |
| 22.1 | 2,571.6 | 460.2 | -175.5 | -37.7 | -22.6 | -- | 3.6 |
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II... clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom. Read more
CEO & Executive Director
Dr. Gary S. Jacob Ph.D.
CEO & Executive Director
Dr. Gary S. Jacob Ph.D.
Headquarters
London
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of OKYO Pharma Ltd ADR (OKYO) is $1.60 (NASDAQ) as of 27-Apr-2026 11:32 EDT. OKYO Pharma Ltd ADR (OKYO) has given a return of 8% in the last 3 years.
Since, TTM earnings of OKYO Pharma Ltd ADR (OKYO) is negative, P/E ratio is not available.
The P/B ratio of OKYO Pharma Ltd ADR (OKYO) is 14.11 times as on 24-Apr-2026, a 173 premium to its peers’ median range of 5.16 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of OKYO Pharma Ltd ADR (OKYO) are Rs 3.35 and Rs 1.31 as of 27-Apr-2026.
OKYO Pharma Ltd ADR (OKYO) has a market capitalisation of $ 84 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in OKYO Pharma Ltd ADR (OKYO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.